Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,174 across all filing types
Latest filing 2024-09-20 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Intimation regarding allotment of 5893 shares under ESOP.
Share Issue/Capital Change Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding the allotment of shares under the company's Employee Stock Option Plan (ESOP). It specifies the number of shares allotted, the increase in issued and paid-up capital, and references compliance with SEBI Listing Regulations. The document is short (1935 characters) and serves as an announcement of a capital change due to share allotment under ESOP. It does not contain financial statements or detailed financial analysis, nor is it a report or presentation. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2024-09-20 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, specifically detailing the loss of share certificates by shareholders. It is addressed to stock exchanges and signed by the company secretary. The content focuses on regulatory compliance related to share certificates, not financial results, management changes, or other report types. It is a regulatory filing related to share certificate loss reporting, which does not fit into other specific categories like Annual Report, Earnings Release, or Director's Dealing. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is short and it is not an announcement of a report but a compliance certificate itself, reinforcing the RNS classification.
2024-09-20 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding the allotment of shares under the company's Employee Stock Option Plan (ESOP). It specifies the number of shares allotted, the increase in issued and paid-up capital, and references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Regulation 30(2). The content is an announcement of a capital change due to share allotment, not a financial report or detailed analysis. The document length is short (1935 characters), and it is clearly an announcement of a share capital change rather than a report or presentation. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA).
2024-09-20 English
Intimation regarding loss of share certificate by the shareholders.
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates reported by shareholders. The document is short (2674 characters) and is a regulatory compliance filing related to share certificate loss, not a financial report or announcement of voting results. It does not contain financial data or management information, nor is it a report or announcement of dividends, capital changes, or legal proceedings. It fits best under Regulatory Filings (RNS) as a compliance certificate filing under SEBI regulations.
2024-09-19 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a compliance certificate submitted under Regulation 39(3) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates for specific shareholders. The document is short (2674 characters) and is a formal notification to stock exchanges regarding shareholder information. It does not contain financial data, management discussion, or any report content. It is not an announcement of voting results, board changes, or capital changes. The document is a regulatory compliance filing related to share certificate loss, which fits best under Regulatory Filings (RNS) as it does not fit any other specific category.
2024-09-19 English
Lupin Enters into a Non-Exclusive Patent Licensing Agreement with Takeda to Commercialize Vonoprazan, a Novel Gastrointestinal Drug in India.
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Lupin Limited has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited to commercialize Vonoprazan Tablets in India. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations, specifically Regulation 30, which pertains to material events or information. The content focuses on the business development and licensing agreement rather than financial results, management changes, or regulatory filings. There are no financial statements, earnings data, or detailed management discussion. The document is not a report but an announcement of a corporate event related to capitalizing on a new product through licensing. Therefore, the most appropriate classification is Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including licensing agreements that impact commercialization and business growth.
2024-09-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.